Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 30 Jul, 08:00 pm
H.C. Wainwright raised its price target for Agios Pharmaceuticals to $55.00 , suggesting a potential 67.05% upside from its current stock price. The biopharmaceutical company reported strong Q2 2026 revenues of $44.75 million , significantly beating the Zacks Consensus Estimate b
Read the full story
Intesa Sanpaolo (OTC: ISNPY) Price Target Raised by RBC Capital Amid Strong Financial Performance and MPS Offer RBC Capital raised its price target for Intesa Sanpaolo to €7.25 from €7.00, while reaffirming an Outperform rating, reflecting confidence in the bank’s
Glaukos (NYSE: GKOS) received an increased price target of $195.00 from H.C. Wainwright, signaling a potential 14.26% upside. The medical technology company reported an adjusted loss of only $0.14 per share , significantly beating analyst estimates, with revenues soaring 50% to a
Headlines provided by Investing.com
